Needham Reiterates Buy on Cartesian Therapeutics, Maintains $41 Price Target

Benzinga · 10/16 10:45
Needham analyst Gil Blum reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $41 price target.